Pediatric pheochromocytoma and paraganglioma: An update;Pheochromocytomes et paragangliomes pédiatriques: Revue de la littérature

Bulletin du Cancer

Volumn 101, Issue 10, 2014, Pages 966-975

  Garnier, Sarah ^a   Réguerre, Yves ^b   Orbach, Daniel ^c   Brugières, Laurence ^d   Kalfa, Nicolas ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c INSTITUT CURIE   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Child; Genetics; Paraganglioma; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANTINEOPLASTIC AGENT; CATECHOLAMINE; METADRENALIN; TUMOR MARKER;

ADVANCED CANCER; BENIGN TUMOR; CANCER STAGING; CANCER SURGERY; CATECHOLAMINE RELEASE; CHILD; CHILDHOOD CANCER; DISEASE SEVERITY; FAMILIAL CANCER; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PEDIATRICS; PERIOPERATIVE PERIOD; PHEOCHROMOCYTOMA; REVIEW; SYMPTOMATOLOGY; TREATMENT INDICATION; TUMOR VOLUME; VON HIPPEL LINDAU DISEASE; ADRENAL GLAND NEOPLASMS; COMPLICATION; GENETIC PREDISPOSITION; GENETICS; RARE DISEASES; SIPPLE SYNDROME;

ADRENAL GLAND NEOPLASMS; CHILD; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RARE DISEASES; TUMOR MARKERS, BIOLOGICAL; VON HIPPEL-LINDAU DISEASE;

EID: 84908703945     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2014.2031     Document Type: Article

References (56)

1. Tischler AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med 2008 ; 132 : 1272-84.
2. Ciftci AO, Tanyel FC, Senocak ME, Buyukpamukcu N. Pheochromocytoma in children. J Pediatr Surg 2001 ; 36 : 447-52.
3. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009 ; 94 : 1853-78.
4. Armstrong R, Sridhar M, Greenhalgh KL, et al. Phaeochromocytoma in children. Arch Dis Child 2008 ; 93 : 899-904.
5. Havekes B, Romijn JA, Eisenhofer G, Adams K, Pacak K. Update on pediatric pheochromocytoma. Pediatr Nephrol 2009 ; 24 : 943-50.
6. Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci 2006 ; 1073 : 30-7.
7. Ludwig AD, Feig DI, Brandt ML, Hicks MJ, Fitch ME, Cass DL. Recent advances in the diagnosis and treatment of pheochromocytoma in children. Am J Surg 2007 ; 194 : 792-6 (discussion 6-7).
8. Waguespack SG, Rich T, Grubbs E, et al. A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2010 ; 95 : 2023-37.
9. Bissada NK, Safwat AS, Seyam RM, et al. Pheochromocytoma in children and adolescents: a clinical spectrum. J Pediatr Surg 2008 ; 43 : 540-3.
10. Weise M, Merke DP, Pacak K, Walther MM, Eisenhofer G. Utility of plasma free metanephrines for detecting childhood pheochromocytoma. J Clin Endocrinol Metab 2002 ; 87 : 1955-60.
11. Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab 2007 ; 3 : 92-102.
12. Fishbein L, Nathanson KL. Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet 2012 ; 205 : 1-11.
13. Letouze E, Martinelli C, Loriot C, et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 201310 ; 23 : 739-52.
14. Eisenhofer G, Walther MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001 ; 86 : 1999-2008.
15. Eisenhofer G, Goldstein DS, Sullivan P, et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. J Clin Endocrinol Metab 2005 ; 90 : 2068-75.
16. Timmers HJ, Chen CC, Carrasquillo JA, et al. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J Natl Cancer Inst 2012 ; 104 : 700-8.
17. Levine DS, Metzger DL, Nadel HR, Oviedo A, Adam MJ, Skarsgard E. Novel use of F-DOPA PET/CT imaging in a child with paraganglioma/pheochromocytoma syndrome. Pediatr Radiol 2011 ; 41 : 1321-5.
18. Wiseman GA, Pacak K, O'Dorisio MS, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med 2009 ; 50 : 1448-54.
19. Schiffman JD, Geller JI, Mundt E, Means A, Means L, Means V. Update on pediatric cancer predisposition syndromes. Pediatr Blood Cancer 2013 ; 60 : 1247-52.
20. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002 ; 346 : 1459-66.
21. Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 2014 ; 14 : 108-19.
22. De Krijger RR, Petri BJ, Van Nederveen FH, et al. Frequent genetic changes in childhood pheochromocytomas. Ann N Y Acad Sci 2006 ; 1073 : 166-76.
23. Grogan RH, Mitmaker EJ, Duh QY. Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control 2011 ; 18 : 104-12.
24. Forman JR,Worth CL, Bickerton GR, Eisen TG, Blundell TL. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis. Proteins 2009 ; 77 : 84-96.
25. Raue F, Frank-Raue K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens) 2009 ; 8 : 23-8.
26. Benn DE, Gimenez-Roqueplo AP, Reilly JR, et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 2006 ; 91 : 827-36.
27. King KS, Prodanov T, Kantorovich V, et al. Metastatic pheochromocytoma/ paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol 2011 ; 29 : 4137-42.
28. Gimenez-Roqueplo AP, Lehnert H, Mannelli M, et al. Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) 2006 ; 65 : 699-705.
29. Gimenez-Roqueplo AP, Burnichon N, Amar L, Favier J, Jeunemaitre X, Plouin PF. Achievements of the COMETE program in the genetics of pheochromocytoma. Bull Acad Natl Med 2008 ; 192 : 105-15 (discussion 15-6).
30. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, et al. Imagingwork-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab 2013 ; 98 : E162-73.
31. Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giache V, Mannelli M. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol 2012 ; 2012 : 872713.
32. Pham TH, Moir C, Thompson GB, et al. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center. Pediatrics 2006 ; 118 : 1109-17.
33. Vanderveen KA, Thompson SM, Callstrom MR, et al. Biopsy of pheochromocytomas and paragangliomas: potential for disaster. Surgery 2009 ; 146 : 1158-66.
34. Pampaloni F, Valeri A, Mattei R, Presenti L, Noccioli B. Experience with laparoscopic adrenalectomy in children. Chir Ital 2006 ; 58 : 45-54.
35. Miller KA, Albanese C, Harrison M, et al. Experience with laparoscopic adrenalectomy in pediatric patients. J Pediatr Surg 2002 ; 37 : 979-82 (discussion -82).
36. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002 ; 26 : 551-66.
37. Beltsevich DG, Kuznetsov NS, Kazaryan AM, Lysenko MA. Pheochromocytoma surgery: epidemiologic peculiarities in children. World J Surg 2004 ; 28 : 592-6.
38. Yoshida T, Ishihara H. Pheochromocytoma presenting as massive hemoptysis and acute respiratory failure. Am J Emerg Med 2009 ; 27 : 626 e3-4.
39. Heloury Y, Muthucumaru M, Panabokke G, Cheng W, Kimber C, Leclair MD. Minimally invasive adrenalectomy in children. J Pediatr Surg 2012 ; 47 : 415-21.
40. Hescot S, Leboulleux S, Amar L, et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2013 ; 98 : 4006-12.
41. McBride JF, Atwell TD, Charboneau WJ, Young Jr. WF, Wass TC, Callstrom MR. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy. J Vasc Interv Radiol 2011 ; 22 : 1263-70.
42. Fitzgerald PA, Goldsby RE, Huberty JP, et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 2006 ; 1073 : 465-90.
43. Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009 ; 27 : 4162-8.
44. International Pediatric Endosurgery G. IPEG guidelines for the surgical treatment of adrenal masses in children. J Laparoendosc Adv Surg Tech A 2010 ; 20 : vii-x.
45. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997 ; 20 : 648-58.
46. Rose B, Matthay KK, Price D, et al. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 2003 ; 98 : 239-48.
47. Mundschenk J, Unger N, Schulz S, et al. Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 2003 ; 88 : 5150-7.
48. Safford SD, Coleman RE, Gockerman JP, et al. Iodine - 131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003 ; 134 : 956-62.
49. Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988 ; 109 : 267-73.
50. Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/ paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 2008 ; 113 : 2020-8.
51. Tanabe A, Naruse M, Nomura K, Tsuiki M, Tsumagari A, Ichihara A. Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma. Horm Cancer 2013 ; 4 : 103-10.
52. Ayala-Ramirez M, Feng L, Habra MA, et al. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer 2012 ; 118 : 2804-12.
53. Szalat A, Fraenkel M, Doviner V, Salmon A, Gross DJ. Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center. Endocrine 2011 ; 39 : 160-6.
54. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB. Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 2009 ; 41 : 697-702.
55. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006 ; 24(3) : 401-6.
56. Sun FK, He HC, Su TW, et al. Multi-targeted tyrosine kinase inhibitor sunitinib: a novel strategy for sporadic malignant pheochromocytoma. Chin Med J (Engl) 2012 ; 125 : 2231-4.